Age-Related Macular Degeneration and Diabetic Retinopathy
This reprint includes contributions from leaders in the field of personalized medicine in ophthalmology. The contributions are diverse and cover pre-clinical and clinical topics. We hope you enjoy reading the articles.
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_84510 | ||
| 005 | 20220621 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220621s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-4209-6 | ||
| 020 | |a 9783036542102 | ||
| 020 | |a 9783036542096 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-4209-6 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a GP |2 bicssc | |
| 072 | 7 | |a PS |2 bicssc | |
| 100 | 1 | |a Westenskow, Peter D. |4 edt | |
| 700 | 1 | |a Ebneter, Andreas |4 edt | |
| 700 | 1 | |a Westenskow, Peter D. |4 oth | |
| 700 | 1 | |a Ebneter, Andreas |4 oth | |
| 245 | 1 | 0 | |a Age-Related Macular Degeneration and Diabetic Retinopathy |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (228 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This reprint includes contributions from leaders in the field of personalized medicine in ophthalmology. The contributions are diverse and cover pre-clinical and clinical topics. We hope you enjoy reading the articles. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Research & information: general |2 bicssc | |
| 650 | 7 | |a Biology, life sciences |2 bicssc | |
| 653 | |a subthreshold micropulse laser | ||
| 653 | |a 577-nm laser | ||
| 653 | |a laser fixed parameters | ||
| 653 | |a diabetic retinopathy | ||
| 653 | |a diabetic macular edema | ||
| 653 | |a optical coherence tomography | ||
| 653 | |a autofluorescence | ||
| 653 | |a real-life | ||
| 653 | |a diabetic macular oedema | ||
| 653 | |a visual prognosis | ||
| 653 | |a indicators | ||
| 653 | |a personalized medicine | ||
| 653 | |a age-related macular degeneration | ||
| 653 | |a choroidal neovascularization | ||
| 653 | |a classification | ||
| 653 | |a machine learning | ||
| 653 | |a type 2 diabetes | ||
| 653 | |a retinopathy | ||
| 653 | |a ethnicity | ||
| 653 | |a general practice | ||
| 653 | |a risk factors | ||
| 653 | |a progression | ||
| 653 | |a glycemic gap | ||
| 653 | |a glucose variability | ||
| 653 | |a ETDRS classification | ||
| 653 | |a biomarkers | ||
| 653 | |a phenotypes | ||
| 653 | |a anti-vascular endothelial growth factor | ||
| 653 | |a diabetic retinopathy severity scale | ||
| 653 | |a panretinal leakage index | ||
| 653 | |a neovascular age-related macular degeneration | ||
| 653 | |a anti-VEGF therapy | ||
| 653 | |a retinal thickness | ||
| 653 | |a visual acuity | ||
| 653 | |a variability | ||
| 653 | |a leakage index | ||
| 653 | |a microaneurysms | ||
| 653 | |a intravitreal aflibercept | ||
| 653 | |a neovascularization | ||
| 653 | |a ultra-widefield fluorescein angiography | ||
| 653 | |a retinal imaging | ||
| 653 | |a quantitative biomarkers | ||
| 653 | |a precision medicine | ||
| 653 | |a autoantibodies | ||
| 653 | |a AT1-receptor | ||
| 653 | |a PAR1 | ||
| 653 | |a VEGF-A | ||
| 653 | |a VEGF-B | ||
| 653 | |a VEGF-receptor 2 | ||
| 653 | |a AMD | ||
| 653 | |a complement system | ||
| 653 | |a semi-quantitative multiplex profilin | ||
| 653 | |a mass spectrometry | ||
| 653 | |a C4 | ||
| 653 | |a vitronectin | ||
| 653 | |a factor I | ||
| 653 | |a genetic variants | ||
| 653 | |a metabolites | ||
| 653 | |a HDL | ||
| 653 | |a central area thickness | ||
| 653 | |a biomarker | ||
| 653 | |a microRNA | ||
| 653 | |a anti-VEGF | ||
| 653 | |a retina | ||
| 653 | |a edema | ||
| 653 | |a OCT | ||
| 653 | |a tomography | ||
| 653 | |a microphysiological systems | ||
| 653 | |a blood-neural barriers | ||
| 653 | |a neurovascular unit | ||
| 653 | |a disease modeling | ||
| 653 | |a 3D models | ||
| 653 | |a organ-on-a-chip | ||
| 653 | |a inner blood-retinal barrier | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/5494 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/84510 |7 0 |z DOAB: description of the publication |